1. Home
  2. IVVD vs GMHS Comparison

IVVD vs GMHS Comparison

Compare IVVD & GMHS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IVVD
  • GMHS
  • Stock Information
  • Founded
  • IVVD 2020
  • GMHS N/A
  • Country
  • IVVD United States
  • GMHS China
  • Employees
  • IVVD N/A
  • GMHS N/A
  • Industry
  • IVVD Biotechnology: Pharmaceutical Preparations
  • GMHS
  • Sector
  • IVVD Health Care
  • GMHS
  • Exchange
  • IVVD Nasdaq
  • GMHS NYSE
  • Market Cap
  • IVVD 123.8M
  • GMHS 106.1M
  • IPO Year
  • IVVD 2021
  • GMHS N/A
  • Fundamental
  • Price
  • IVVD $0.51
  • GMHS $1.19
  • Analyst Decision
  • IVVD Strong Buy
  • GMHS
  • Analyst Count
  • IVVD 3
  • GMHS 0
  • Target Price
  • IVVD $7.52
  • GMHS N/A
  • AVG Volume (30 Days)
  • IVVD 1.7M
  • GMHS 280.3K
  • Earning Date
  • IVVD 05-08-2025
  • GMHS 01-01-0001
  • Dividend Yield
  • IVVD N/A
  • GMHS N/A
  • EPS Growth
  • IVVD N/A
  • GMHS 98.09
  • EPS
  • IVVD N/A
  • GMHS 0.05
  • Revenue
  • IVVD $25,384,000.00
  • GMHS $145,236,749.00
  • Revenue This Year
  • IVVD $606.63
  • GMHS N/A
  • Revenue Next Year
  • IVVD $83.30
  • GMHS N/A
  • P/E Ratio
  • IVVD N/A
  • GMHS $23.80
  • Revenue Growth
  • IVVD N/A
  • GMHS N/A
  • 52 Week Low
  • IVVD $0.36
  • GMHS $0.96
  • 52 Week High
  • IVVD $2.74
  • GMHS $17.49
  • Technical
  • Relative Strength Index (RSI)
  • IVVD 38.07
  • GMHS N/A
  • Support Level
  • IVVD $0.46
  • GMHS N/A
  • Resistance Level
  • IVVD $0.56
  • GMHS N/A
  • Average True Range (ATR)
  • IVVD 0.06
  • GMHS 0.00
  • MACD
  • IVVD 0.01
  • GMHS 0.00
  • Stochastic Oscillator
  • IVVD 29.24
  • GMHS 0.00

About IVVD Invivyd Inc.

Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.

About GMHS GAMEHAUS HOLDINGS INC

Gamehaus Holdings Inc is a technology-driven mobile game publishing company for small- and medium-sized game developers. It built a diverse game portfolio across multiple genres, including social casino, match, simulation, RPG, puzzle, and bingo, others, and distributes mobile games created by developer partners across a wide range of gaming markets, including in countries such as the U.S., the U.K., Australia, Germany, France, Canada, Brazil, Japan, and India, among others. The company offers a comprehensive package of services covering all aspects of the game life cycle, including (i) game development, (ii) screening and pre-publication testing, (iii) user acquisition, and (iv) monetization.

Share on Social Networks: